Oklahoma City, OK – (September 13, 2016) Cytovance® Biologics, Inc., a leading biopharmaceutical contract manufacturing organization announces the appointment of Jenny Chen to Chief Financial Officer.
Jenny Chen has 20 years of successful experience in global finance operations across manufacturing, aviation, and banking industries in the United States, The Netherlands, and China. Prior to joining Cytovance, she was the Corporate Controller for Maxcess International, a multinational industrial equipment manufacturing company with significant global footprints in North America, Europe, and Asia. She has championed numerous projects including global SAP system implementation, mergers and acquisitions, optimization of corporate legal structure, and ITdeployment. She has also directed SEC reporting, business valuation, continuous process improvement, corporate finance transformation, and long-term strategic planning.
“Jenny’s impressive background in finance makes her a great fit for her new role at Cytovance,” said President & CEO Darren Head. “We welcome her to our team and look forward to her contributions in the financial and contractual management of Cytovance’s rapid global growth”.
“I am honored to be recognized by Darren Head, President and CEO of Cytovance,” said Jenny Chen, “I’m excited to join an executive team at Cytovance that has been so smart and financially savvy with its operations,” said Jenny. “I am impressed by the team’s dedication to solid strategic growth, its devotion to Cytovance employees and customers and its commitment to positively impacting the world as a core priority of the company.”
Jenny holds a B.S. in Accounting from Jinan University, China and an M.S. in Accounting from Oklahoma State University. She is a Certified Public Accountant and a Certified Management Accountant. She has chaired the Members in Industry Committee of Oklahoma Society of CPAs. She currently serves on the Board of Financial Executives International and Institute of Management Accountants.
Cytovance® Biologics is a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. In addition to its cGMP manufacturing services, the company offers process development, cGMP cell banking and support services from its Oklahoma City state-of-the-art facilities.